Hot Features
Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company’s lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age a... Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company’s lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1801 for treating staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 for the treatment of papulopustular rosacea; and BTX 1204A for treating atopic dermatitis. The company was incorporated in 1984 and is based in Melbourne, Australia. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.001 | -4.54545454545 | 0.022 | 0.023 | 0.02 | 9267299 | 0.02137044 | DE |
| 4 | -0.009 | -30 | 0.03 | 0.031 | 0.02 | 13218775 | 0.0241791 | DE |
| 12 | -0.027 | -56.25 | 0.048 | 0.048 | 0.02 | 23455692 | 0.03304212 | DE |
| 26 | -0.084 | -80 | 0.105 | 0.15 | 0.02 | 16154595 | 0.0476162 | DE |
| 52 | -0.324 | -93.9130434783 | 0.345 | 0.35 | 0.02 | 13278820 | 0.09602865 | DE |
| 156 | -0.079 | -79 | 0.1 | 0.535 | 0.02 | 8248674 | 0.20189905 | DE |
| 260 | -0.049 | -70 | 0.07 | 0.535 | 0.02 | 5501392 | 0.18960216 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.